DNA:NYE-Ginkgo Bioworks Holdings (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 8.09

Change

+0.16 (+2.02)%

Market Cap

USD 0.46B

Volume

0.66M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TECH Bio-Techne Corp

+0.13 (+0.26%)

USD 8.03B
BHVN Biohaven Pharmaceutical Holdin..

-0.27 (-1.69%)

USD 1.64B
RCUS Arcus Biosciences Inc

+0.15 (+1.75%)

USD 0.91B
NUVB Nuvation Bio Inc

+0.04 (+1.77%)

USD 0.77B
CYBN Cybin Inc

+0.78 (+11.61%)

USD 0.15B
ADCT ADC Therapeutics SA

+0.45 (+23.81%)

USD 0.14B
PLX Protalix Biotherapeutics Inc

+0.01 (+0.60%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.05 (-3.05%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

+0.01 (+0.40%)

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

+0.12 (+7.19%)

USD 0.05B

ETFs Containing DNA

SPAK 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.62% 50% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.62% 50% F 11% F
Trailing 12 Months  
Capital Gain -73.60% 40% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.60% 40% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.21% 24% F 4% F
Dividend Return -16.21% 24% F 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 102.28% 41% F 7% C-
Risk Adjusted Return -15.85% 38% F 15% F
Market Capitalization 0.46B 86% B+ 47% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector